Allena Pharmaceuticals (NASDAQ:ALNA) and Erytech Pharma (NASDAQ:ERYP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, risk, earnings and dividends.
This is a summary of recent ratings and recommmendations for Allena Pharmaceuticals and Erytech Pharma, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Volatility & Risk
Allena Pharmaceuticals has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, Erytech Pharma has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.
Institutional & Insider Ownership
84.4% of Allena Pharmaceuticals shares are held by institutional investors. Comparatively, 14.7% of Erytech Pharma shares are held by institutional investors. 36.7% of Allena Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares Allena Pharmaceuticals and Erytech Pharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Allena Pharmaceuticals and Erytech Pharma’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Allena Pharmaceuticals||N/A||N/A||-$21.65 million||($4.80)||-1.82|
|Erytech Pharma||N/A||N/A||-$37.89 million||($3.33)||-2.34|
Erytech Pharma is trading at a lower price-to-earnings ratio than Allena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Allena Pharmaceuticals beats Erytech Pharma on 7 of the 10 factors compared between the two stocks.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
About Erytech Pharma
ERYTECH Pharma S.A., a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia. It is preparing for the launch of a pivotal Phase III clinical trial of eryaspase in the United States and Europe. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria and with Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. ERYTECH Pharma S.A. was founded in 2004 and is based in Lyon, France.
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.